Cargando…

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

Chronic myelogenous leukemia (CML) is caused by the constitutively active tyrosine kinase Bcr-Abl and treated with the tyrosine kinase inhibitor (TKI) imatinib. However, emerging TKI resistance prevents complete cure. Therefore, alternative strategies targeting regulatory modules of Bcr-Abl in addit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grebien, Florian, Hantschel, Oliver, Wojcik, John, Kaupe, Ines, Kovacic, Boris, Wyrzucki, Arkadiusz M., Gish, Gerald D., Cerny-Reiterer, Sabine, Koide, Akiko, Beug, Hartmut, Pawson, Tony, Valent, Peter, Koide, Shohei, Superti-Furga, Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cell Press 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202669/ https://www.ncbi.nlm.nih.gov/pubmed/22000011 http://dx.doi.org/10.1016/j.cell.2011.08.046

Ejemplares similares

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
por: Wojcik, John, et al.
Publicado: (2010)

The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis
por: Mian, Afsar A., et al.
Publicado: (2019)

Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation
por: Filippakopoulos, Panagis, et al.
Publicado: (2008)

Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis
por: Nieborowska-Skorska, Malgorzata, et al.
Publicado: (1999)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
por: Schmidt, Nina, et al.
Publicado: (2022)

A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL
por: Rix, Uwe, et al.
Publicado: (2013)

Evaluation of Stat5 as a potential drug target in bcr/abl-induced leukemias
por: Hölbl, Andrea, et al.
Publicado: (2008)

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
por: Hoelbl, Andrea, et al.
Publicado: (2010)

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis
por: Berger, A, et al.
Publicado: (2014)

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
por: Warsch, Wolfgang, et al.
Publicado: (2012)

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
por: Reckel, Sina, et al.
Publicado: (2017)

Targeting allosteric regulatory modules in oncoproteins: “Drugging the Undruggable”
por: Hantschel, Oliver, et al.
Publicado: (2011)

Autophagy is Essential to Suppress Cell Stress and to Allow BCR-Abl-Mediated Leukemogenesis
por: Altman, Brian J., et al.
Publicado: (2010)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

Bcr-Abl: one kinase, two isoforms, two diseases
por: Reckel, Sina, et al.
Publicado: (2017)

Selective Targeting of SH2 Domain–Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies
por: Kükenshöner, Tim, et al.
Publicado: (2017)

Autoinhibition of Bcr-Abl through Its SH3 Domain
por: Smith, Kristen M., et al.
Publicado: (2003)

BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP
por: Feng, Lin, et al.
Publicado: (2023)

Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis
por: Gerboth, S, et al.
Publicado: (2018)

A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia
por: Menzl, Ingeborg, et al.
Publicado: (2019)

Monoubiquitinated Fanconi Anemia D2 (FANCD2-Ub) Is Required for BCR-ABL1 Kinase -Induced Leukemogenesis
por: Koptyra, Mateusz, et al.
Publicado: (2011)

c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells
por: Waldron, Todd, et al.
Publicado: (2011)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Cell biology: A key driver of therapeutic innovation
por: Hantschel, Oliver, et al.
Publicado: (2012)

The SH2 Domain Regulates c-Abl Kinase Activation by a Cyclin-Like Mechanism and Remodulation of the Hinge Motion
por: Dölker, Nicole, et al.
Publicado: (2014)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo
por: Yu, Weidong, et al.
Publicado: (2008)

Low Expression of miR-196b Enhances the Expression of BCR-ABL1 and HOXA9 Oncogenes in Chronic Myeloid Leukemogenesis
por: Liu, Yue, et al.
Publicado: (2013)

Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis
por: Tamai, Minori, et al.
Publicado: (2022)

Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
por: Berger, Angelika, et al.
Publicado: (2014)

Mig6 Is a Sensor of EGF Receptor Inactivation that Directly Activates c-Abl to Induce Apoptosis during Epithelial Homeostasis
por: Hopkins, Sarah, et al.
Publicado: (2012)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

P62(dok), a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210(bcr-abl)
por: Di Cristofano, Antonio, et al.
Publicado: (2001)

Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics
por: Reckel, S, et al.
Publicado: (2017)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Mutational Analysis of SH2B3 in Korean Patients With BCR-ABL1 Negative Myeloproliferative Neoplasm
por: Kim, Namhee, et al.
Publicado: (2016)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Conformational Determinants of Phosphotyrosine Peptides Complexed with the Src SH2 Domain
por: Nachman, Joseph, et al.
Publicado: (2010)

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
por: Winger, Jonathan A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_4id0v78jd4719mohuqs7bib0u7